Elevated serum progesterone during in vitro fertilization treatment and the risk of ischemic placental disease

Pregnancy Hypertens. 2021 Jun:24:7-12. doi: 10.1016/j.preghy.2021.02.004. Epub 2021 Feb 13.

Abstract

Background: Elevated progesterone on the day of human chorionic gonadotropin (hCG) administration is associated with decreased live birth rates in IVF cycles. The association with adverse pregnancy outcomes is unknown.

Objectives: Assess the association between serum progesterone on the day of hCG administration and the risk of ischemic placental disease [IPD; preeclampsia, placental abruption, and/or small for gestational age (SGA)].

Methods: We conducted a retrospective cohort study of autologous fresh IVF cycles resulting in delivery between 2005 and 2018. All IVF procedures were conducted at a large, university-affiliated infertility center. Patients were divided into tertiles based on their serum progesterone level on the day of hCG administration; the lowest tertile served as the reference group. We identified pregnancies complicated by preeclampsia and placental abruption using ICD-9/10 codes and medical record review. We defined SGA as < 10th percentile using U.S. growth curves.

Results: The cohort included 166 deliveries in the lowest tertile of progesterone (0.2-0.73 ng/ml), 166 deliveries in the middle (0.64-1.05 ng/ml) and 167 deliveries in the highest tertile (1.05-5.6 ng/ml). Compared with the lowest tertile, the risk of IPD was greater in the middle (RR 1.6; 95% CI 1.1-2.5) tertile after adjustment for age, parity, number of oocytes retrieved, and estradiol. The highest tertile was also not associated with an increased risk of IPD.

Conclusion: In an IVF population, elevated serum progesterone in the range of 0.64-1.05 ng/mL on the day of hCG administration was associated with a small increased risk of IPD.

Keywords: IVF; Ischemic placental disease; Serum progesterone.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Embryo Transfer / adverse effects
  • Embryo Transfer / methods*
  • Female
  • Fertilization in Vitro / adverse effects*
  • Humans
  • Infertility, Female / therapy*
  • Ovulation Induction / methods*
  • Placenta / blood supply*
  • Placenta / pathology
  • Placenta Diseases / epidemiology*
  • Placenta Diseases / etiology
  • Pregnancy
  • Pregnancy Outcome
  • Pregnancy Rate
  • Progesterone / blood*
  • Treatment Outcome

Substances

  • Biomarkers
  • Progesterone